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Abstract
The delivery of therapeutics via nanoscaled vehicles for solid cancer treatment can be enhanced by
the incorporation of a targeting capability. Here, we describe a new method for assembling a
targeted nanoparticle that utilizes the reversible covalent complexation between boronic acids and
diols to achieve a targeted nanoparticle for the delivery of anti-cancer drug, camptothecin (CPT).
CPT is conjugated to a biocompatible, hydrophilic copolymer of mucic acid and PEG (MAP).
When this polymer-drug conjugate is placed in water, it self-assembles into MAP-CPT
nanoparticles of ca. 30 nm (diameter) and slightly negative zeta potential. The antibody Herceptin
is attached to a boronic acid via a polyethylene glycol (PEG) spacer, and this boronic acid-
containing targeting moiety is complexed with the diol-containing MAP to form a targeted MAP-
CPT nanoparticle. The addition of Herceptin targeting agent to the MAP-CPT nanoparticles yields
targeted MAP-CPT nanoparticles with increased nanoparticle size to ca. 40 nm (diameter). The
main mechanisms of CPT release from MAP-CPT nanoparticles are found by in vitro analysis to
be hydrolysis and nanoparticle disruption by fat. Cellular uptake of nanoparticles is enhanced by
70% compared to non-targeted version by the incorporation of a single Herceptin antibody
targeting agent per nanoparticle. This single Herceptin antibody targeted MAP-CPT nanoparticle
system carries ca. 60 CPT molecules per nanoparticle and shows prolonged plasma circulation
with an elimination half-life of 21.2 h and AUC value of 2766 μg.h/ml at a 10 mg CPT/kg tail
vein injection in mice.
Introduction
Nanoparticles are finding application for the delivery of a broad range of therapeutic and
imaging agents, some of which are currently being investigated in human clinical trials (1,
2). When nanoparticles are employed for the delivery of therapeutics to solid cancers, they
rely upon the enhanced permeability and retention (EPR) effect to accumulate in the tumors
(3). After reaching the tumor site by the EPR effect, nanoparticles containing targeting
agents that can engage cancer cell surface receptors are shown to achieve uptake into cancer
cells in amounts exceeding those of non-targeted nanoparticles with similar size and surface
charge (4–6).
Our research group has been involved in translating two polymer-based nanoparticles from
the laboratory to the clinic. The first, CRLX101 (previously known as IT-101) is a ca. 30 nm
(diameter), non-targeted nanoparticle composed of a cyclodextrin-polymer conjugate of the
anti-cancer drug camptothecin (CPT) (7). The second, CALAA-01, is a ca. 70 nm (diameter)
targeted (human transferrin protein) nanoparticle comprised of a cyclodextrin-polymer and
siRNA (8, 9). The method of assembling the targeting moiety onto the CALAA-01
nanoparticle involves the formation of inclusion complexes of adamantane with the
cyclodextrins in the polymer (8). Since the method of assembling CRLX101 utilizes
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inclusion complex formation between the cyclodextrins in the polymer and the conjugated
CPT, the targeting methodology employed with CALAA-01 is not amenable for CRLX101.
Because of this issue and others that were encountered as these nanoparticles were translated
to the clinic, we have been exploring new ways of assembling targeted nanoparticles that
could carry any type of payload. Here, we describe a methodology to create targeted
nanoparticles that involves the use of boronic acid-diol complexes.
Boronic acids have been used: (i) in a variety of pharmaceutical agents, (ii) in creating
devices to sense sugars and (iii) in compounds to create drug delivery materials and devices
(10). For example, the complexation of boronic acids with diols has recently been employed
to assemble cross-linked micelles (11, 12). Here, we demonstrate a new method for the
assembly of targeted nanoparticles that employs boronic acid complexation with diols. That
is, nanoparticles are assembled using polymers that have sugars in their backbone, e.g.,
mucic acid, to provide a repeating unit that contains vicinal diols. Nanoparticle targeting
agents are conjugated with flexible spacing groups, e.g., polyethylene glycol (PEG), and
terminated with a boronic acid. These targeting moieties are then assembled onto the surface
of the nanoparticle via the reversible, covalent bonding between the boronic acid and the
surface vicinal diols of the polymer (Scheme 1). This nanoparticle system can have
numerous functionalities that allow for the assembly with a wide variety of therapeutic and
imaging agents (13). For example, small hydrophobic drug molecules like CPT can be
conjugated to the polymer backbone and self-assembled into nanoparticles.
In this study, we report on an antibody (Herceptin) targeted, polymer-based nanoparticle
system for the delivery of CPT that utilizes the complexation of boronic acids on the
antibody targeting moiety and vicinal diols on the polymer for assembly of the targeted
nanoparticle. CPT was conjugated onto a biocompatible hydrophilic copolymer backbone of
mucic acid and PEG (MAP). This conjugate, when placed in water self-assembled into
nanoparticles. Addition of the antibody targeting agent was achieved by exploiting the
complexation between boronic acids in the targeting moiety and the mucic acid repeats in
the polymer (Scheme 1).
Experimental Procedures
General
All commercially purchased reagents and solvents including anhydrous and HPLC grades
were used without further purification. Boc-L-aspartic acid 4-benzyl 1-(N-
hydroxysuccinimide) ester (Boc-Asp(OBzl)-OSu) was purchased from Bachem (Bubendorf,
Switzerland). Disuccinimidyl propionate poly(ethylene glycol) (diSPA-PEG, MW 3400)
was purchased from SunBio (South Korea). Campthothecin was obtained from Boehringer
Ingelheim (Ingelheim, Germany). 3-carboxylphenylboronic acid and 3-carboxy 5-
nitrophenylboronic acid were purchased from Alfa Aesar (Ward Hill, MA). Amine
polyethylene glycol carboxylic acid (NH2-PEG-CO2H, MW 5000) was purchased from
JenKem Technology USA (Allen, TX). Herceptin® (Trastuzumab) was obtained from Dr.
Y. Yen at the City of Hope (Duarte, CA). BT-474, MCF-7, SKBR-3 and MDA-MB-231
breast cancer cell lines were purchased from American Type Culture Collection (Manassas,
VA). Female BALB/c mice were purchased from Jackson Laboratory (Bar Habor, ME).
Mice plasma was processed from fresh blood collected from female BALB/c mice. All other
reagents were purchased from Sigma (St Louis, MO).
1H, 13C and 19F NMR spectra were recorded on either a 500 MHz or 600 MHz spectrometer
(Inova, Varian). Mass spectrometry was carried out using a LCQ ion trap mass spectrometer
(Finnigan, Thermo) by direct infusion electrospray ionization or MALDI-TOF mass
spectrometer (Voyager DE™-PRO, Applied Biosystems).
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Concentrations of unconjugated CPT and polymer-bound CPT were analyzed on a HPLC
system (Agilent) equipped with a fluorescence detector (excitation 370 nm, emission 440
nm) and a reverse phase column (Synergi 4 μm Hydro-RP 80 Å, Phenomenex) complete
with guard column. 50% acetonitrile, 50% potassium phosphate buffer (10 mM, pH 4) was
used as the eluent at a flow rate of 0.5 ml/min.
Absorbance and other fluorescence measurements were taken on a microplate reader
(Infinite 200, Tecan).
Preparation and Characterization of MAP-CPT Nanoparticles
1. Mucic acid dimethyl ester—120 ml of methanol and 0.4 ml of concentrated sulfuric
acid were added to 5 g (22.8 mmol) of mucic acid. This mixture was refluxed at 85 °C
overnight under constant stirring. Solids were filtered, washed with methanol, recrystallized
and dried under vacuum overnight to yield 8 g (71%) of mucic acid dimethyl ester. 1H NMR
((CD3)2SO) δ 4.88–4.91 (d, 2H), 4.78–4.81 (m, 2H), 4.28–4.31 (d, 2H), 3.77–3.78 (d, 2H),
3.63 (s, 6H). ESI/MS (m/z): 261.0 [M+Na]+.
2. Protected mucic acid diamine—60 ml of methanol, 5.25 g (32.7 mmol) of N-Boc-
ethylenediamine and 5.7 ml (32.7 mmol) of N, N-diisopropylethylamine (DIPEA) were
added to 3 g (12.6 mmol) of mucic acid dimethyl ester. This reaction mixture was refluxed
at 85 °C overnight under constant stirring. Solids were filtered, washed with methanol,
recrystallized and dried under vacuum to give 4.65 g (75%) of product. 1H NMR
((CD3)2SO) δ 7.72 (t, 2H), 6.82 (t, 2H), 5.13–5.15 (d, 2H), 4.35–4.38 (d, 2H), 4.08–4.11 (d,
2H), 3.78–3.80 (d, 2H), 2.95–3.15 (m, 8H), 1.36 (s, 18). ESI/MS (m/z): 517.1 [M+Na]+.
3. Mucic acid diamine—8 g (16.2 mmol) of protected mucic acid diamine was
transferred to a flask containing 3 N HCl in methanol (160 ml) and reacted for 6 h at room
temperature under constant stirring. Precipitate was filtered, washed with methanol and
vacuum dried overnight to yield 5.69 g (96%) of mucic acid diamine. 1H NMR ((CD3)2SO)
δ 7.93–7.99 (m, 8H), 5.31–5.34 (d, 2H), 4.57 (d, 2H), 4.10–4.17 (d, 2H), 3.82 (d, 2H), 3.32–
3.38 (m, 4H), 2.82–2.86 (m, 4H). ESI/MS (m/z): 295.1 [M+H]+.
4. Mucic acid di(Asp(OBzl)-Boc)—9.27 g (22.1 mmol) of Boc-Asp(OBzl)-OSu in 75
ml of acetonitrile and 2.88 ml (35.8 mmol) of pyridine was added to 2.7 g (7.35 mmol) of
mucic acid diamine dissolved in 45 ml water. This reaction mixture was refluxed at 60 °C
overnight under constant stirring. Acetonitrile was removed by rotavap and resulting
precipitate was recrystallized from hot water and dried under vacuum to yield 2.03 g (31%)
mucic acid di(Asp(OBzl)-Boc). 1H NMR ((CD3)2SO) δ 7.93 (t, 2H), 7.75 (t, 2H), 7.29–7.35
(m, 10H), 7.05 (d, 2H), 5.11 (t, 2H), 5.06 (s, 4H), 4.34–4.39 (d, 2H), 4.25–4.30 (d, 2H),
4.10–4.12 (d, 2H), 3.77–3.79 (d, 2H), 3.11–3.15 (m, 8H), 2.53–2.78 (m, 4H), 1.36 (s, 18H).
ESI/MS (m/z): 927.4 [M+Na]+.
5. Mucic acid di(Asp(OBzl)-amine)—6 ml (80.8 mmol) of trifluoroacetic acid was
slowly added to 2 g (2.21 mmol) of mucic acid di(Asp(OBzl)-Boc) dissolved in 18 ml of
dichloromethane on an ice bath. The reaction was allowed to proceed for 4 h in ice bath.
Solvent was removed, precipitate recrystallized with tetrahydrofuran and dried on vacuum to
yield 1.74 g (84%) of product. 1H NMR ((CD3)2SO) δ 8.46 (t, 2H), 8.21 (s, 6H), 7.79 (t,
2H), 7.32–7.38 (m, 10H), 5.19 (t, 2H), 5.14 (s, 4H), 4.41 (s, 2H), 4.11–4.14 (d, 2H), 4.02–
4.06 (d, 2H), 3.81 (s, 2H), 3.11–3.23 (m, 8H), 2.79–3.02 (m, 4H). ESI/MS (m/z): 705.4 [M
+H]+.
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6. Mucic acid di(Asp-amine)—511 mg (13.5 mmol) of 20 w % palladium hydroxide on
carbon was transferred to 1.26 g (1.35 mmol) of mucic acid di(Asp(OBzl)-amine) dissolved
in 50 ml of methanol. Reaction vessel was sealed and vented with argon. Hydrogen gas was
added via double-layered balloon for 24 h. Catalyst was filtered away, solvent removed and
precipitate dried on vacuum. This was then reconstituted in water, filtered with a 0.2 μm
membrane filter (Acrodisc) and lyophilized to yield 711 mg (70%) of product. 1H NMR
((CD3)2SO) δ 8.44 (t, 2H), 8.19 (broad, 6H), 7.80 (t, 2H), 5.22 (t, 2H), 4.48 (s, 2H), 4.12 (s,
2H), 3.94–3.99 (m, 2H), 3.80 (s, 2H), 3.11–3.23 (m, 8H), 2.70–2.85 (m, 4H). ESI/MS (m/z):
525.2 [M+H]+.
7. MAP (Mucic Acid containing Polymer)—111 mg of mucic acid di(Asp-amine)
(0.15 mM) and 500 mg of diSPA-PEG3.4kDa (0.15 mM) were dried under vacuum for 6 h.
3.5 ml of anhydrous dimethyl sulfoxide was added under argon to dissolve the reactants. 82
μl (0.47 mM) of anhydrous DIPEA was then added under argon and reaction was allowed to
proceed for 40 h at room temperature under constant stirring. Reaction mixture was then
dialyzed with 10 kDa MWCO membrane filter device (Amicon) 4 times, filtered through a
0.2 μm membrane filter (Acrodisc) and lyophilized to yield 466 mg (81%) MAP. GPC (for
medium MAP): Mn = 55.5 kDa, Mw = 75.3 kDa, Mw/Mn = 1.36. 1H NMR ((CD3)2SO, for
medium MAP) δ 8.07 (d, 1H), 8.04 (d, 1H), 7.83 (t, 1H), 7.77 (t, 1H), 7.69 (t, 2H), 4.43 (td,
2H), 4.10 (d, 2H), 3.75 (ddt, 2H), 3.55 (t, 4.3H), 3.42–3.52 (PEG peak, 330H), 3.05–3.16
(m, 8H), 2.39–2.53 (m, 4H), 2.34 (t, 4.3H). 13C NMR (D2O, for medium MAP) δ 175.7,
174.9, 174.0, 172.9, 66.5, 69.6, 70.6, 50.6, 38.8, 38.3, 36.5, 35.7.
8. Absolute molecular weight determination of MAP—The absolute determination
of molecular weights does not require standards for calibration. The values were determined
on a GPC system equipped with an Agilent pump, degasser and autosampler, double gel
permeation columns (PL aquagel-OH 40 8 μm 300 × 7.5 mm, Polymer Laboratory) in series
connected to a multi-angle laser light scattering (MALS) detector (DAWN HELEOS,
Wyatt) and a refractive index (RI) detector (Optilab rEX, Wyatt). PBS (1x, 0.02 w/v %
sodium azide, pH 7.4) was used as the eluent at a flow rate of 0.7 ml/min. Specific refractive
increment, dn/dc was measured by batch injection of various concentrations of MAP
dissolved in PBS into Optilab rEX at 0.2 ml/min.
9. Molecular weight control of MAP—Molecular weight of MAP was controlled by the
amount of tertiary base, N, N-diisopropylethylamine (DIPEA) added to the reaction. After
dissolving equal molar ratios of mucic acid di(Asp-amine) and diSPA-PEG (3.4 kDa) in
anhydrous dimethyl sulfoxide, different equivalents (1.1, 1.6 and 2) of anhydrous DIPEA to
amine groups on mucic acid di(Asp-amine) were added. The reactions were then carried out
and the polymers processed as per the methods described in section 7 (vide supra). Three
polymers of differing molecular weights were prepared and denoted as short, medium and
long.
10. 20-O-glycinylcamptothecin trifluoroacetic acid salt (CPT-glyTFA)—20-O-
glycinylcamptothecin trifluoroacetic acid salt (CPT-glyTFA) was synthesized as previously
reported (14).
11. MAP-CPT conjugate—403 mg (0.22 mM on -CO2H basis) of MAP was dissolved in
20 ml of anhydrous dimethyl sulfoxide. To this was added 167 mg (0.87 mM) of EDC and
75 mg (0.65 mM) of NHS dissolved in 6 ml of anhydrous dimethyl sulfoxide, 340 mg (0.65
mM) of 20-O-glycinylcamptothecin trifluoroacetic acid salt (CPT-glyTFA) dissolved in 6
ml of anhydrous dimethyl sulfoxide and 114 μl (0.65 mM) of anhydrous DIPEA under
argon. After overnight reaction under constant stirring, the reaction mixture was dialyzed
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against dimethyl sulfoxide 3 times and water 2 times using 10 kDa MWCO membrane
(Spectra/Por 7). Any insoluble material was removed by centrifugation and supernatant was
filtered with a 0.2 μm filter (Acrodisc). A portion of this clear yellow solution was
lyophilized for yield determination and percent CPT conjugation analysis. The remaining
was formulated into 0.9 w/v% saline and stored at −20 °C.
12. CPT content in MAP-CPT—Weight percent of CPT in MAP-CPT was determined
by the intrinsic fluorescence of CPT. MAP-CPT was dissolved in dimethyl sulfoxide at 10
mg/ml. This was diluted into 0.1 mg/ml with 1 N NaOH and incubated overnight.
Fluorescence was measured at excitation 370 nm, emission 440 nm, and compared to that of
known concentrations of CPT.
13. Nanoparticle composition—Nanoparticle compositions were analyzed as per the
methods described in section 8 (vide supra) except gel permeation columns were bypassed.
Dn/dc value of MAP-CPT nanoparticles was measured by batch injection of various
concentrations of MAP-CPT nanoparticles dissolved in PBS into Optilab rEX at 0.2 ml/min.
This allowed for the molecular weight determination of MAP-CPT nanoparticles. The
number of MAP-CPT conjugates per nanoparticle was then calculated from this data.
14. Nanoparticle size and surface charge—Particle size and zeta potential
measurements were determined by dynamic light scattering (DLS) using a ZetaPALS
instrument (Brookhaven Instruments, Holtsville, NY). Effective hydrodynamic diameter was
recorded and averaged from 10 runs at 1 min each. Zeta potential measurements were
collected in 1 mM KCl solution for three sets of 10 runs at a target residual of 0.012, and the
results were averaged.
15. Nanoparticle morphology—Nanoparticle morphology was visualized by cryo-
electron microscopy (cryo-EM). Glow discharged Quantifoil holey carbon grid (SPI
Supplies) was loaded into an automated climate-controlled plunge-freezer (Vitrobot, FEI)
and 3 μl of sample was applied. Grid was blotted, drained, plunged into liquid ethane,
transferred and stored in liquid nitrogen. Samples were visualized under cryogenic
temperatures with transmission electron microscope (Tecnai T12, FEI) equipped with a
cryo-specimen holder. Acceleration voltage was set at 120 kV.
Preparation and Characterization of Targeted MAP-CPT Nanoparticles
1. PBA-PEG-CO2H (3-amide-PEG(5kDa)-carboxylic acid phenylboronic acid)—
To 200 mg (1.21 mM) of 3-carboxyphenylboronic acid dissolved in 5 ml of anhydrous
tetrahydrofuran was added 18.7 μl (0.24 mM) of anhydrous dimethylformamide under
argon. This reaction vessel was transferred into an ice bath and 195 μl (2.89 mM) of oxalyl
chloride was slowly added under argon. Reaction was allowed to proceed under vent and
constant stirring for 2 h at room temperature. Solvent and excess reagent were removed
under vacuum. 37 mg (0.2 mM) of this dried acyl chloride compound was dissolved in 15
ml of anhydrous dichloromethane under argon. To this was added 500 mg (0.1 mM) of NH2-
PEG(5kDa)-CO2H and 52 μl (0.3 mM) of dry DIPEA under argon. After overnight reaction
under constant stirring, solvent was removed under vacuum and the dried product was
reconstituted in 0.5 N HCl. This solution was passed through a 0.2 μm filter (Acrodisc) and
dialyzed against water with a 3 kDa MWCO membrane filter device (Amicon) until constant
pH was attained. The supernatant was then filtered with a 0.2 μm filter (Acrodisc) and
lyophilized to yield 377 mg (73%) of PBA-PEG-CO2H. 1H NMR ((CD3)2SO) δ 12.52 (s,
1H), 8.39 (t, 1H), 8.22 (s, 1H), 8.14 (s, 2H), 7.88 (d, 1H), 7.82 (d, 1H), 7.39 (t, 1H), 3.99 (s,
2H), 3.35–3.62 (PEG peak). MALDI-TOF (m/z): 5600 g/mol (NH2-PEG5kDa-CO2H, 5400
g/mol).
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2. nitroPBA-PEG-CO2H (3-amide-PEG(5kDa)-carboxylic acid, 5-
nitrophenylboronic acid)—Synthesis of nitroPBA-PEG-CO2H was performed in the
same way as for PBA-PEG-CO2H except the starting material was 3-carboxy 5-
nitrophenylboronic acid. The reaction yielded 393 mg (76%) of nitroPBA-PEG-CO2H. 1H
NMR ((CD3)2SO) δ 12.52 (s, 1H), 8.89 (t, 1H), 8.72 (s, 1H), 8.68 (s, 1H), 8.64 (s, 1H), 8.61
(s, 2H), 3.99 (s, 2H), 3.35–3.62 (PEG peak). MALDI-TOF (m/z): 5600 g/mol (NH2-
PEG5kDa-CO2H, 5400 g/mol).
3. pKa determination for PBA—pKa of PBA was found by measuring the change in
absorbance of PBA as it converted from trigonal (in low pH) to tetrahedral (in high pH)
conformation. To a solution of 10−3 M PBA in 0.1 M PBS, pH 7.4 was titrated 1 N NaOH.
pH was recorded and corresponding samples were removed for absorbance measurements at
268 nm.
4. Binding constant determination between PBA and MAP—A three component
competitive assay involving fluorescent dye Alizarin Red S, PBA and MAP (diol
containing) was used to determine the binding constant between PBA and MAP. This
technique was developed by Springsteen and Wang (15). Briefly, the association constant
Keq1 for Alizarin Red S-PBA complex was determined by changes in fluorescence as PBA
was titrated into Alizarin Red S. MAP was then titrated into a solution containing Alizarin
Red S and PBA. The addition of the MAP perturbed the first equilibrium due to MAP
competing with Alizarin Red S for binding to PBA. Changes in fluorescence were measured
and the association constant Keq between PBA and MAP was then determined.
Measurements were performed in 0.1 M PBS at pH 7.4.
5. Herceptin-PEG-nitroPBA (Herceptin-PEG(5kDa)-5-nitrophenylboronic acid)
—36 mg (6.4 μM) of nitroPBA-PEG-CO2H, 12.3 mg (64 μM) of EDC and 11.1 mg (96
μM) of NHS were dissolved in 2.4 ml of 0.1 M MES buffer, pH 6.0. This mixture was
reacted for 15 min on a rotating shaker at room temperature. Excess reactants were dialyzed
away with 3 kDa MWCO membrane filter device (Amicon). This activated carboxylic acid
PEG compound was added to 20 mg (0.14 mM) of Herceptin in 0.1 M PBS, pH 7.2.
Reaction was carried out on a rotating shaker at room temperature for 2 h and then dialyzed
4 times with 50 kDa MWCO membrane filter device (Amicon) against 1x PBS at pH 7.4.
MALDI-TOF: average conjugation of 1 to 2 nitroPBA-PEG per antibody.
6. Formulation of targeted MAP-CPT nanoparticles—Herceptin-PEG-nitroPBA was
added to the medium MAP-CPT nanoparticles to form targeted MAP-CPT nanoparticles at a
ratio of one Herceptin per nanoparticle in 1x PBS, pH 7.4.
7. Particle size, surface charge and morphology—The methods used for the
targeted nanoparticle were the same as for the non-targeted nanoparticles as described in
Preparation and Characterization of MAP-CPT Nanoparticles sections 14 and 15 (vide
supra).
Cellular Uptake Studies
24 well plates were seeded with either BT-474 (in RPMI-1640 medium supplemented with
10% fetal calf serum) or MCF-7 (in Dulbecco’s Modified Eagle medium supplemented with
10% fetal calf serum) (Cellgro, Manassas, VA) at 20,000 cells per well and kept at 37 °C in
a humidified oven with 5% CO2. After 40 h, media were replaced with 0.3 ml of fresh media
containing either medium MAP-CPT (40 μg CPT/ml), medium MAP-CPT with free
Herceptin at 10 mg/ml, targeted MAP-CPT (40 μg CPT/ml) at varying targeting densities or
targeted MAP-CPT with free Herceptin at 10 mg/ml. Transfection was conducted for 30 min
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at 37 °C. Formulations were then removed and cells washed twice with cold PBS. 200 μl of
RIPA buffer was added per well for cell detachment and lysis. Lysed cells were then
incubated at 4 °C for 15 min and centrifuged at 14,000 g for 10 min at 4 °C. A portion of the
supernatant was used for protein quantification via BCA assay. To another portion was
added an equal amount of 0.1 N NaOH, this was incubated at room temperature overnight
and fluorescence was measured at 370/440 nm using known concentrations of MAP-CPT as
standard.
In Vitro Release Studies
Release of CPT from short, medium, long MAP-CPT nanoparticles and targeted MAP-CPT
nanoparticles were conducted at 0.32 mg CPT/ml in 1x PBS at pH 6.5, 7 or 7.4; BALB/c
mice plasma, human plasma, and 1x PBS at pH 7.4 containing 3 mg/ml of low density
lipoprotein (LDL), or 100 units/ml of Butyrylcholinesterase (BCHE) or a combination of
LDL and BCHE.
Media pipetted into 96 well plates were incubated at 37 °C in a humidified oven for 2 h for
equilibration. Formulations were mixed into the relevant media and placed back into the
oven. Samples were taken out at predetermined time points and immediately frozen at −80
°C until time for analysis. For release in BALB/c mice plasma and in human plasma,
incubation was carried out in a humidified oven at 37 °C with 5% CO2 to maintain the
carbonic acid/bicarbonate buffer system, the major pH buffer system in plasma at
physiological pH levels.
The amount of unconjugated CPT was determined by first mixing 10 μl of sample with 10
μl of 0.1 N HCl and incubating at room temperature for 30 min. 80 μl of methanol was then
added and the mixture incubated at room temperature for 3 h for protein precipitation. This
mixture was centrifuged at 14,000 g for 10 min at 4 °C, supernatant was filtered with a 0.45
μm filter (Millex-LH), diluted 20 folds with methanol and 10 μl of the resulting solution
injected into HPLC. The peak area of the eluted CPT (at 7.8 min) was compared to that of
control. To measure the total amount of CPT, 10 μl of sample was mixed with 6.5 μl of 0.1
N NaOH. This solution was incubated at room temperature for 1 h for CPT to be released
from parent polymer. 10 μl of 0.1 N HCl was then added to convert the carboxylate CPT
form to the lactone form. 73.5 μl of methanol was subsequently added and mixture
incubated for 3 h at room temperature. The sample was then centrifuged and processed as
above. Polymer-bound CPT concentration was determined from the difference between total
CPT and unconjugated CPT concentrations.
Cytotoxicity Assays
Cells were kept at 37 °C in a humidified oven with 5% CO2. BT-474, MCF-7, SKBR-3 and
MDA-MB-231 cell lines were incubated in RPMI-1640 medium, Dulbecco’s Modified
Eagle medium, McCoy’s 5A Modified medium and Dulbecco’s Modified Eagle medium
respectively (all supplemented with 10% fetal calf serum). 3,000 cells per well were plated
into 96 well plates. After 24 h, media was removed and replaced with fresh media
containing different concentrations of medium MAP, nitroPBA-PEG, CPT, medium MAP-
CPT nanoparticles, targeted MAP-CPT nanoparticles or Herceptin. After 72 h of incubation,
formulations were replaced with fresh media, and 20 μl of CellTiter 96® AQueous One
Solution cell proliferation assay (Promega) was added per well. This was incubated for 2 h
in a humidified oven at 37 °C with 5% CO2 before absorbance measurements at 490 nm.
Wells containing untreated cells were used as controls.
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Pharmacokinetic Studies
All animals were treated as per National Institute of Health Guidelines for Animal Care and
approved by California Institute of Technology Institutional Animal Care and Use
Committee. Formulations were administered via bolus tail vein injection into 12 – 16 weeks
old female BALB/c mice. At predetermined time points, blood was collected via saphenous
vein bleed with blood collection tubes (Microvette CB 300 EDTA, Sarstedt). Samples were
immediately centrifuged at 10,000 g, 4 °C for 15 min and supernatant removed and stored at
−80 °C until time for analysis. Analyses for unconjugated and polymer-bound CPT were as
per the methods described in the section In vitro Release Studies (vide supra). Non-
compartmental modeling software PK Solutions 2.0 by Summit Research Services
(Montrose, CO) was used for pharmacokinetic data analysis.
Results and Discussions
Preparation and Characterization of MAP-CPT Nanoparticles
The synthesis methodology of the MAP-CPT conjugate and its assembly into MAP-CPT
nanoparticles is outlined in Scheme 2. Mucic acid was modified to contain both amino and
carboxyl groups to allow for polymerization with PEG (amine group) and for conjugation of
CPT (carboxyl group), respectively. It was observed via 19F NMR that the mucic acid
di(Asp-amine) formed was the trifluoroacetic acid salt by comparison to a standard (2-
(trifluoromethyl)acetophenone). Therefore, for the polymerization reaction between mucic
acid di(Asp-amine) and diSPA-PEG to proceed, a base was required for the deprotonation of
-NH3+ group into the reactive -NH2 form. Here, the tertiary base N, N-
diisopropylethylamine (DIPEA) was used. Supplementary Fig. 1 shows representative NMR
data for the MAP polymers. The polymer end groups were determined to be -PEG-CO2H
by 1H NMR comparison of PEG and mucic acid di(Asp-amine) peak integrals. The
molecular weight of MAP can be controlled by the amount of DIPEA added per NH3+ group
on mucic acid di(Asp-amine) (Table 1). As the amount of DIPEA was increased, an increase
in viscosity of the reaction mixture was observed. Three polymers were prepared and their
properties are listed in Table 1.
The absolute molecular weights of the different MAP samples were measured using multi-
angle laser light scattering (MALS) and refractive index (RI) detections. A refractive index
increment (dn/dc) value of 0.134 ml/g was found for the medium MAP. This dn/dc value
along with MALS and RI data were used to determine the number average molecular weight
(Mn), weight average molecular weight (Mw) and polydispersity (Mw/Mn) of the MAP
samples (Table 1).
CPT modified at 20-OH position has been reported to show significant reduction in
deactivation caused by ring opening of the lactone (16). We therefore used CPT modified at
this site with a glycine linker, CPT-gly, as was done previously with IT-101 (14). The CPT-
gly was conjugated onto MAP to form MAP-CPT conjugate by standard EDC coupling
technique (Scheme 2). The amount of CPT conjugated onto the three MAP polymers is
reported in Table 1.
Upon addition of water, the MAP-CPT conjugates self-assemble into nanoparticles since
CPT is very soluble in dimethyl sulfoxide but not soluble to any significant amount in water.
To determine the number of MAP-CPT conjugates per MAP-CPT nanoparticle, dn/dc values
of MAP-CPT nanoparticles were found, and the nanoparticles were characterized by MALS
and RI detection. From these data, the molecular weight of each MAP-CPT nanoparticle was
determined. Since the molecular weights of MAP-CPT conjugates were known, the MAP-
CPT nanoparticles were found to be composed of 2 to 3 MAP-CPT conjugates. This finding
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along with the observation that all MAP-CPT nanoparticles have approximately the same
size (ca. 30 nm in diameter) suggests that the nanoparticles have different packing densities.
MAP-CPT nanoparticles have an average particle size of ca. 30 nm (by DLS measurements)
and a slightly negative surface charge (by Zeta Potential measurements). The negative
surface charge is presumably due to the presence of unconjugated carboxylic acid groups on
the MAP backbone. Cryo-EM was used to visualize the medium MAP-CPT nanoparticles in
their native environment. Spherical nanoparticles with a narrow size range of 20–40 nm are
observed (Fig. 1A).
Preparation and Characterization of Targeted MAP-CPT Nanoparticles
To prepare a targeted nanoparticle, the covalent, reversible binding property between
boronic acids and MAP (diol containing) was used. The binding constant between
phenylboronic acid (PBA) and MAP is low at ca. 20 M−1. To increase the binding constant,
PBAs with electron withdrawing groups on the phenyl ring were employed to increase the
acidity of the boron atom and thus elevate the binding constant with MAP. Commercially
available 3-carboxyPBA and 3-carboxy 5-nitroPBA were converted into acyl chlorides
using oxalyl chloride (Scheme 3). These acyl chloride species were then reacted with NH2-
PEG-CO2H to form PBA-PEG-CO2H and nitroPBA-PEG-CO2H, respectively (Scheme 3).
The addition of bases DMF and DIPEA were required for the synthesis reactions to proceed.
However, the presence of these bases resulted in tetrahedral adduct formations with acidic
PBA. To remove these adducts, work up in 0.5 N HCl with subsequent equilibration to
neutral pH by dialysis against water was carried out.
pKa values of the modified PBAs were determined by absorbance changes due to
conformational change of PBA from trigonal to tetrahedral form as the pH was increased
(Table 2). PBA with electron withdrawing groups resulted in lower pKa’s, with nitroPBA-
PEG-CO2H having the lowest pKa of 6.8. Thus, at physiological pH, most of the PBA was
present in the reactive anionic tetrahedral form. Binding constants between PBA and MAP
were found by competitive binding with Alizarin Red S in 0.1 M PBS, pH 7.4. Because of
the low pKa value and high binding constant with MAP observed for nitroPBA-PEG-CO2H,
it was chosen as the linker between Herceptin and MAP-CPT nanoparticles.
The conjugation reaction between Herceptin and nitroPBA-PEG-CO2H proceeded via EDC
coupling (Scheme 4). An average of 1 to 2 PEGs were attached per Herceptin antibody.
An average size of ca. 40 nm was observed for targeted MAP-CPT nanoparticles by DLS
and cryo-EM (Table 1 and Fig. 1B). This increase in ca. 10 nm from the non-targeted
nanoparticle suggests the attachment of Herceptin to the nanoparticle (the amount was ca.
one Herceptin antibody per nanoparticle). Indeed, from cryo-EM images, the targeted
nanoparticles were not spherical but appeared to have protrusions indicating the attachment
of antibodies. The surface charge of targeted MAP-CPT nanoparticles was slightly higher
than MAP-CPT nanoparticles due to the presence of a positively charged Herceptin at pH
7.4 (pI of Herceptin, 9.2 (17)).
Cellular Uptake Studies
BT-474, a HER2 overexpressing human breast cancer cell line, was used to examine the
cellular uptake of Herceptin targeted MAP-CPT nanoparticles versus the non-targeted
nanoparticles. MCF-7, a HER2 negative breast cancer cell line, was used as a negative
control. It was observed that one Herceptin-PEG-nitroPBA per nanoparticle was sufficient
to achieve ca. 70% greater uptake in BT-474 cell line compared to the non-targeted
nanoparticle (Fig. 2A). Uptake of the targeted MAP-CPT in BT-474 cells showed inhibition
in the presence of free Herceptin (Fig. 2B). In contrast, uptake of MAP-CPT nanoparticles in
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MCF-7 exhibited no dependence on targeting or on presence of free Herceptin (Fig. 2B).
These data indicate that there is receptor mediated uptake in the BT-474 cells by the targeted
MAP-CPT nanoparticles via engagement of the HER2 receptor. Cellular uptake of both the
targeted and non-targeted MAP-CPT nanoparticles also occurred via nonspecific fluid phase
endocytosis.
In Vitro Release Studies
Release of CPT from the short, medium and long MAP-CPT nanoparticles and from the
targeted MAP-CPT nanoparticles all exhibited first-order kinetics. Release half-lives of CPT
from the short, medium and long MAP-CPT nanoparticles were very similar in all
conditions tested, while longer half-lives for the targeted MAP-CPT were observed (Table
3). A strong dependence of release rate with pH was observed. As the pH increased from 6.5
to 7.4, the release half-lives reduced from 338 h to 58 h for the short, medium and long
MAP-CPT nanoparticles. These data indicate that hydrolysis plays an important role in the
release of CPT. A release half-life of 59 h was observed in BALB/c mice plasma, while a
significantly lower half-life of 38 h was obtained in human plasma for the short, medium
and long MAP-CPT nanoparticles. It is known that mice plasma contains more esterase
activity than human plasma, while human plasma contains more “fat” than mouse plasma.
Therefore, to understand the differences in release rates between human and mice plasma,
the contributions of esterase and fat to CPT release rates were individually tested.
Butyrylcholinesterase (BCHE) is present in both mice and human plasma and was used to
test esterase contribution to the release rate. Low density lipoprotein (LDL) was chosen to
test the contribution of “fat” to the release rate. These components were constituted in PBS
(pH 7.4). It was found that the presence of BCHE did not affect release rate (half-life of 61 h
compared to 58 h in PBS, pH 7.4, for the short, medium and long MAP-CPT nanoparticles).
However, the addition of LDL dramatically increased the release rates. This effect is likely
due to nanoparticle disruption by competing hydrophobic interactions. Therefore,
nanoparticle disruption by the presence of “fat”, and the subsequent CPT cleavage by
hydrolysis appears to be another main mechanism of CPT release from MAP-CPT
nanoparticles. In vitro release from the Herceptin targeted MAP-CPT nanoparticles shows
longer half-lives than the non-targeted versions. It is possible that the presence of Herceptin
with a pI of 9.2 [17] increased the stability of the negatively charged nanoparticles by
electrostatic interactions, and thus shielded the nanoparticles from some of the competing
hydrophobic interactions.
Cytotoxicity Assays
In vitro cytotoxicities of medium MAP, nitroPBA-PEG, CPT, medium MAP-CPT
nanoparticles, targeted MAP-CPT nanoparticles and Herceptin were evaluated in two
HER2+ breast cancer cell lines (BT-474, SKBR-3) and two HER2- breast cancer cell lines
(MCF-7, MDA-MB-231) (Table 4).
Medium MAP and nitroPBA-PEG gave IC50 values of above 500 μM and 1000 μM
(highest concentrations tested), respectively, indicating minimal toxicity. IC50
concentrations of CPT, medium MAP-CPT nanoparticles and targeted MAP-CPT
nanoparticles were based on the content of the CPT. It is noted that CPT was released
gradually from medium MAP-CPT nanoparticles and targeted MAP-CPT nanoparticles (see
In Vitro Release Studies). Additionally, nanoparticle uptake by cells results in long release
times due to the acidic nature of the endosomes. These factors contribute to the observed
higher IC50 values for the medium MAP-CPT nanoparticles and targeted MAP-CPT
nanoparticles compared to CPT (Table 4). In HER2+ cell lines, the targeted MAP-CPT
nanoparticles gave lower IC50 values compared to MAP-CPT alone, while in HER2- cell
lines, targeting did not affect the IC50. BT-474 was the most resistant cell line to CPT, and
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consequently to medium MAP-CPT nanoparticles. The addition of Herceptin at
concentrations of 0.001–0.5 μM to BT-474 or SKBR-3 cells resulted in a constant cell
viability of ca. 60% as compared to a no treatment control. The lack of a true IC50 value
over this concentration range for these cell lines has been observed previously (18). There
were no effects observed in HER2- cell lines at Herceptin concentrations of up to 0.5 μM.
Pharmacokinetic Studies
The nanoparticles displayed a biphasic profile with a fast redistribution phase (α) and a long
elimination phase (β). The elimination phase for the medium MAP-CPT nanoparticles was
prolonged with a half-live of 16.6 h and a high AUC value of 2298 μg.h/ml. In contrast,
mice injected with CPT alone at 10 mg/kg showed fast clearance, with AUC of only 1.6
μg.h/ml (19). Targeting of the medium MAP-CPT nanoparticles affected the
pharmacokinetic profile by increasing the redistribution phase and prolonging the
elimination phase to 21.2 h with a high AUC value of 2766 μg.h/ml. The amount of
unbound CPT in plasma for both nanoparticles was low at all time points. The PK data are
similar to those of CRLX101 (7) that is currently being investigated in a number of Phase II
clinical trials.
Summary
We report here a new methodology for creating targeted nanoparticles that uses boronic
acid-diol complexation as a way to assemble the targeting agents onto the polymer-based
nanoparticles. The specific example of assembling an antibody targeted nanoparticle
delivery system for the small hydrophobic drug, CPT, was used to demonstrate the assembly
method. The targeted nanoparticle was composed of a biocompatible copolymer of mucic
acid and PEG (MAP) onto which the anti-cancer drug CPT was conjugated. Targeting was
achieved by attaching boronic acids to the targeting moiety of choice, in this case Herceptin
antibody, and the subsequent complexation via boronic acid-diol formation with the mucic
acid repeats in the MAP polymer. A ca. 40 nm nanoparticle size and a slightly negative
surface charge allowed for its long circulation in vivo with an elimination half-life of 21.2 h
and an AUC value of 2766 μg.h/ml at a 10 mg/kg CPT injection in mice. This extended
circulation will be helpful in exploiting the EPR effect for localization in solid tumors.
Nanoparticle cellular uptake was enhanced by 70% via targeting by receptor mediated
uptake compared to the non-targeted version. This single antibody targeted system contained
ca. 60 CPT molecules per nanoparticle. We have recently completed the initial in vivo
testing of the nanoparticles described in this work in nude mice bearing BT-474 tumors. The
targeted nanoparticles were able to show complete tumor regression while the non-targeted
versions did not. These antitumor results along with further PK and biodistribution data will
be reported elsewhere (20).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Cryo-EM images of (A) medium MAP-CPT nanoparticles, (B) targeted MAP-CPT
nanoparticles
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Figure 2.
Cellular uptake of (A) targeted MAP-CPT nanoparticles at increasing ratio of Herceptin-
PEG-nitroPBA to nanoparticle in BT-474, (B) medium MAP-CPT nanoparticles or targeted
MAP-CPT nanoparticles with or without free Herceptin (10 mg/ml) in BT-474 and MCF-7
cell lines.
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Scheme 1.
Targeted MAP-CPT nanoparticle delivery system. MAP, copolymer of mucic acid and
polyethylene glycol; CPT, camptothecin; BA, boronic acid.
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Scheme 2.
Synthesis of MAP-CPT nanoparticles.
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Scheme 3.
Synthesis of (A) PBA-PEG-CO2H and (B) nitroPBA-PEG-CO2H.
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Scheme 4.
Synthesis of Herceptin-PEG-nitroPBA.
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Table 1
Characterization of MAP, MAP-CPT conjugate, MAP-CPT nanoparticles and targeted MAP-CPT
nanoparticles
Short Medium Long
MAP
Base added (equivalent)a 1.1 1.6 2
MWb (kDa) 20 65 102
Polydispersityc 1.22 1.36 1.13
# repeat units (n) 5–7 15–21 25–30
MAP-CPT conjugate MW
b
 (kDa) 22 75 114
wt % CPT conjugated 9.8 12.7 10.1
MAP-CPT nanoparticle
# conjugates/particle 2–3 2–3 2–3
# CPT/particle ~14 ~60 ~72
particle size (nm) ~30 ~30 ~30
zeta potential (mV) −1.3+/−0.6 −0.5+/−0.5 −0.8+/−0.5
Targeted MAP-CPT nanoparticle
# Herceptin/particle 1
particle size (nm) ~40
zeta potential (mV) −0.4+/−0.6
a
Equivalent amount of N, N-diisopropylethylamine (DIPEA) added per amine group in mucic acid di(Asp-amine).
b
MW, molecular weight determined as (Mw+Mn)/2; Mw, weight average molecular weight; Mn, number average molecular weight.
c
Polydispersity determined as Mw/Mn.
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Table 2
pKa values and binding constants of various PBAs (phenylboronic acids) to MAP
pKa Binding Constant with MAP (M−1)
PBA 8.8 20
PBA-PEG-CO2H 8.3 520
nitroPBA-PEG-CO2H 6.8 1420
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Table 3
In vitro release half-lives (t1/2) of CPT from short, medium and long MAP-CPT nanoparticles and from
targeted MAP-CPT nanoparticles in various media
PBS t1/2 (h) pH 6.5 pH 7 pH 7.4
Short, medium, long MAP-CPT 338 178 58
Targeted MAP-CPT 396 204 78
Plasma t1/2 (h) Mice Human
Short, medium, long MAP-CPT 59 38
Targeted MAP-CPT 63 46
PBS pH 7.4 t1/2 (h) LDLa BCHEb LDL + BCHEc
Short, medium, long MAP-CPT 45 61 44
Targeted MAP-CPT 62 76 62
Abbreviations: PBS, phosphate buffered saline; LDL, low density lipoprotein; BCHE, Butyrylcholinesterase.
a
PBS, pH 7.4, containing 3 mg/ml LDL.
b
PBS, pH 7.4, containing 100 units/ml BCHE.
c
PBS, pH 7.4, containing 3 mg/ml LDL and 100 units/ml BCHE.
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